← Back to Search

Mindfulness Meditation for Pulmonary Hypertension (MMPH) for Pulmonary Hypertension (MMPH Trial)

N/A
Waitlist Available
Led By Tania Von Visger
Research Sponsored by State University of New York at Buffalo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Self-identified as URM person
Have access to a mobile phone
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and at the end of the study intervention (week #8)
Awards & highlights

MMPH Trial Summary

This trial will study a new 8-week mindfulness program to see if it can help people with pulmonary hypertension manage their symptoms. The program will include two live Zoom sessions, six recorded sessions, and daily mindfulness meditation using a mobile app.

Eligible Conditions
  • Pulmonary Hypertension

MMPH Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You self-identify as a person from an underrepresented minority group.
Select...
You own a mobile phone.
Select...
You are willing to participate in the mindfulness program for the entire study.

MMPH Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and at the end of the study intervention (week #8)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and at the end of the study intervention (week #8) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in Depressive Symptoms on the 27-point Patient Health Questionnaire-9 Scales (PHQ-9) to Week #8.
Secondary outcome measures
Change From Baseline in Mindfulness Level on the 40-point Cognitive and Affective Mindfulness Scale-Revised (CAMS-R) to Week #8.
Change From Baseline in PH-related Quality of Life on the 50-point EmPHasis-10 Scales to Week #8.

MMPH Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment ArmExperimental Treatment1 Intervention
This treatment Arm will receive MMPH intervention first, while the wait-listed group waits until this group is complete. Then the wait-listed group will receive the same intervention after the first group completes it.
Group II: Comparison Arm or Waited List ArmActive Control1 Intervention
This active comparator Arm will not receive MMPH intervention at the beginning. They will receive the intervention once the Treatment Group completed the intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mindfulness Meditation for Pulmonary Hypertension (MMPH)
2022
N/A
~20

Find a Location

Who is running the clinical trial?

State University of New York at BuffaloLead Sponsor
244 Previous Clinical Trials
49,442 Total Patients Enrolled
National Center for Advancing Translational Sciences (NCATS)NIH
316 Previous Clinical Trials
390,638 Total Patients Enrolled
Tania Von VisgerPrincipal InvestigatorState University of New York at Buffalo School of Nursing

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants being welcomed into this research endeavor?

"Per the information on clinicaltrials.gov, recruitment for this experiment has concluded as of October 5th 2022. Despite its completion, there are presently 760 other medical studies that require participants' participation."

Answered by AI

Who else is applying?

What state do they live in?
Washington
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
~5 spots leftby Mar 2025